4 results
Approved WMOCompleted
To assess accuracy and reliability of new-to-market CGM systems in patients with type 1 diabetes.
Not approvedWill not start
Measuring tFUS-dependent changes in behaviour (in our target tasks) when targeting deep brain regions [Behavioral Objective]
Approved WMOCompleted
To assess the local and systemic safety and tolerability of continued ABBV-951 treatment delivered as a CSCI for 24 hours daily.
Approved WMOCompleted
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.